Now running for almost two decades, we are delighted to release an agenda for our 17th annual
Pain Therapeutics conference, taking place on 22nd & 23rd May 2017 in Central London, UK.
Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, the 17th annual show will provide a focal point for the industry to assess new innovations in effective and safe pain management.
Created with an expert advisory board, this year's programme will feature a selection of carefully handpicked keynote addresses and case studies to capture the latest developments and novel approaches in pain therapy and drug development. It will hone in on key topics such as; product formulation; opioid addiction; translational pain research; breakthroughs in drug discovery; advantages and limitations of animal models; and present exclusive new findings from phase II clinical trials.
Benefits of Attending
- Awareness of new guideline on the clinical development of medicinal products intended for the treatment of pain
- Strategies and real case studies to minimise risk of opioid dependence
- Evaluate the translation gap with case studies from a pre-clinical and clinical perspective
- Explore the latest in the area of Neuropathic pain for 2017 with the latest case studies from top pharma companies
- Examine the use of animal models to study pain pathways
Plus An Interactive Half-Day Post-Conference Workshop | Wednesday 24th May 2017
Animal Models of Pain: A Critical AssessmentWorkshop Leader: Dr Steven G. Kamerling, Senior Research Director and Therapeutic Area Head for Pain, Inflammation, Oncology and Cardiac Disease, Global Therapeutics Research, Zoetis
8.30 - 12.30
Speakers
- Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester
- Geert Jan Groeneveld, Research Director, Centre for Human Drug Research
- Iain Chessell, Head of Neuroscience, AstraZeneca
- Ian Bell, Principal Scientist, MSD, USA
- Joseph Stauffer, Chief Medical Officer, Cara Therapeutics, Inc.
- Karin Hygge Blakeman, Head of Medical Affairs Nordics, Grunenthal Sweden AB
- Keith Phillips, Senior Research Scientist , Lilly UK
- Mary Hannaman, President , NeuroDigm
- Narender Gavva, Scientific Director, Amgen
- Mikhail Kalinichev, Director, in vivo Neurology, Ipsen Innovation
- Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
- Richard Butt, CEO, Apollo Therapeutics
- Shaloo Pandhi, Global Program Medical Director, Novartis
- Stephen Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Therapeutics
- Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, Zoetis
- Tanja Ouimet, Head of Clinical Operations, Pharmaleads
- Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutica NV
- Thomas Christoph, Head of Pharmacology and Biomarker Development, Grunenthal GmbH
- Thomas Klein, Associate Director Translational Science, Mundipharma Research
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Venue
Copthorne Tara HotelScarsdale Place, Kensington
London, United Kingdom
